

Philippines : Second Health System Enhancement to Address and Limit COVID-19 Project (HEAL-2)

1. Project Information

Project ID:	P000490	Instrument ID:	L0490A
Member:	Philippines	Region:	South-Eastern Asia
Sector:	Public Health	Sub-sector:	N/A
Instrument type:	<input checked="" type="checkbox"/> Loan:300.00 USD million <input type="checkbox"/> Guarantee	Co-financier(s):	Asian Development Bank
ES category:	C	Borrowing Entity:	Department of Finance, Philippines
Implementing Entity:	Department of Health, Philippines		
Project Team Leader:	Wanli Fang		
Project Team Members:	Lily Jin, Team Member; Bernardita Saez, Project Counsel; Christopher Damandl, Alternate Counsel; Yogesh Malla, OSD - Financial Management Specialist; Calvin Quek, OSD - Environment Specialist; Calvin Quek, OSD - Social Development Specialist; Yunlong Liu, OSD - Procurement Specialist; Chang Tian, Project admin;		
Completed Site Visits by AIIB:	Aug, 2021 August 20-27, 2021: Virtual loan inception mission with the Asian Development Bank (lead financier), the Department of Finance and the Department of Health (the implementing agency) Mar, 2022 The Project holds an update meeting every other two weeks on matters including the disbursement, procurement of vaccines, and project financial management. This update meeting is attended by AIIB and ADB through video conference. The 24th update meeting was held on March 18th.		
Planned Site Visits by AIIB:	Apr, 2022 Review mission with Department of Health is planned for April 2022 through video conference.		
Current Red Flags Assigned:	0		
Current Monitoring Regime:	Regular Monitoring		
Previous Red Flags Assigned:	0		
Previous Red Flags Assigned Date:	2021/09		

2. Project Summary and Objectives

This Project is supported under AIIB's COVID-19 Crisis Recovery Facility, together with the lead co-financier, Asian Development Bank (ADB), for the procurement of vaccines eligible under ADB's Asia Pacific Vaccine Access Facility (APVAX) program. The Project will provide critically needed vaccines to assist the Government of the Philippines in mitigating adverse health, social, and economic impacts caused by the COVID-19 pandemic. The objective is to support the Government of the Philippines for rapid procurement of eligible COVID-19 vaccines for up to 50 million Filipinos (43.8% of the total population) to be vaccinated against COVID-19 by 2024. ADB, the lead co-financier has provided a loan of USD400 million.

3. Key Dates

Approval:	Mar. 25, 2021	Signing:	Mar. 26, 2021
-----------	---------------	----------	---------------

Effective:	May. 10, 2021	Restructured (if any):	
Orig. Closing:	Sep. 30, 2024	Rev. Closing (if any):	

4. Disbursement Summary (USD million)

Contract Awarded:		Cancellation (if any):	0.00
Disbursed:	295.63	Most recent disbursement (amount/date):	9.43/Sep. 29, 2021
Undisbursed:	4.37	Disbursement Ratio (%) ¹ :	98.54

5. Project Implementation Update

ADB and AIIB are actively working with the Government of Philippines to monitor the Project during implementation. AIIB receives regular updates on the Project through joining the bi-weekly meetings together with ADB and the implementing agency. As of March 17th, 2022, 85.6 million doses of vaccine were procured and 100% of procured doses were received. Among them 51.8 million doses were administered.

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	<p>As of March 17th, 2022, 85.6 million doses of vaccine were procured and 100% of procured doses were received. Among them 51.8million doses were administered.</p> <p>VIMS implementation is progressing. DICT (Department of Information Communications Technology) is actively providing training and support regionally and at contact centers. The implementation of VIMS is well underway to ensure successful roll out of a master-listing and registry of immunization records.</p>	<p>The Project's environmental and social risk and impacts have been assessed in accordance with the provision of ADB's Safeguard Policy Statement published in 2009. ADB's SPS will apply to the Project in lieu of AIIB's ESP as permitted under AIIB's Environmental and Social Policy (ESP).</p> <p>The Project has been categorized based on ADB's SPS as follows: environment as Category C; involuntary resettlement as Category C as no resettlement is expected; indigenous peoples as Category C as no impact is expected. The focus during monitoring will be on expanding and strengthening social safety nets for the most vulnerable groups, as the Project is not expected to have any adverse environmental or social safeguard impacts.</p> <p>Gender and socially inclusive protocol and guidelines are closely monitored and carried out in coordination with the Health</p>	Vaccine procurement has been made through direct procurement by the Government of Philippines with qualified suppliers. The contracts are reviewed by ADB and AIIB before making direct payments to the suppliers, with no-objection letters issued by the ADB.

¹ Disbursement Ratio is defined as the volume (e.g. the dollar amount) of total disbursed amount as a percentage of the net committed volume.

		Promotion Bureau on matters ranging from communication, programs, campaigns and content. Technical assistance has been requested from Health Promotion Bureau (HPB) to stimulate the demand for DOH's COVID-19 vaccine through communication and campaign efforts. The goals are to improve confidence in receiving vaccine and address barriers to vaccination among vulnerable or marginalized groups. HPB developed a draft Local Health System Health Promotion Playbook for Equity-based vaccination.	
--	--	--	--

Financial Management:

The financial management system is effectively being operated. Two DOH finance staff have been assigned to the Project, and a financial management consultant has been retained to support the team.

6. Status of the Grievance Redress Mechanism (GRM)

Project communication with respect to vaccination has commenced. There is no resettlement or land acquisition as part of this Project. The Project will further develop information material containing objectives, activities, timelines, relevant contact information, and a brief summarizing the Project in simple language and infographics targeting wider audience, including the poor and women. The documents will be made available to the public in print and distributed during outreach activities.

7. Results Monitoring

Details can be found below

Project Objective Indicators #1

Up to 110 million doses of COVID-19 vaccines procured and delivered to the country by 2024.

Year	Target	Actual	Comments, if any
Sep. 01, 2021	5 m doses	37.2 m doses	85.5 million doses of vaccines were procured and 37.2 million doses have been delivered as the end of September 2021.
Sep. 01, 2022	40 m doses	N/A	
Sep. 01, 2023	65 m doses	N/A	
Sep. 01, 2024	110 m doses	N/A	

Project Objective Indicators #2

Vaccine Information Management System (VIMS) launched by 2023.

Year	Target	Actual	Comments, if any
Sep. 01, 2021	N/A	VIMS implementation has commenced	Department of Information and Communications Technology (DICT) has worked closely with the National Vaccine Operations Center (NVOC) which is tasked to analyze and report on vaccine supply

			and inoculation through National Covid-19 Vaccine Dashboard. VIMS in its basic format is in operation and is being further developed with more capabilities. Data is being collected from various sites through existing systems. The system is continually updated. A soft launch took place in April 2021
Sep. 01, 2022	Launch - with updates to the system.	N/A	
Sep. 01, 2023	Launch the system	N/A	

Intermediate Result Indicators #1

Gender and socially inclusive protocol and guidelines on the deployment and administration of vaccines, addressing the specific needs of marginalized women and women in especially difficult circumstances, developed, approved, and disseminated by 2023.

Year	Target	Actual	Comments, if any
Sep. 01, 2021	N/A	Communication by the DOH has commenced.	
Sep. 01, 2022	Gender and socially inclusive protocol and guidelines	N/A	
Sep. 01, 2023	Gender and socially inclusive protocol and guidelines	N/A	

Remarks:
